Kate Therapeutics
Kate Therapeutics was a San Diego-based biotechnology company that developed next-generation gene therapies for muscle and heart diseases using its proprietary MyoAAV capsid platform; the company was acquired by Novartis in 2024 for approximately $1.1 billion.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kate Therapeutics does
Kate Therapeutics was a privately held biotechnology company headquartered in San Diego, California, that developed next-generation gene therapies targeting skeletal muscle and heart diseases. Founded circa 2020, the company emerged from stealth mode in June 2023 alongside a $51 million Series A financing led by Versant Ventures and Westlake Village BioPartners, with participation from OUP (Osage University Partners) and UF Innovate Ventures. It was subsequently acquired by Novartis in 2024 for approximately $1.1 billion.
The company's core technology centered on a proprietary MyoAAV capsid platform combined with novel gene therapy cargo technologies, enabling targeted delivery of therapeutic genes to muscle and cardiac tissues. The MyoAAV capsid was reported to achieve comparable or improved muscle targeting at approximately 100-fold lower doses than earlier gene therapy approaches (specifically AT132), directly addressing the liver toxicity issues that had derailed earlier neuromuscular gene therapy programs. The disclosed pipeline included KT430 for X-linked myotubular myopathy (XLMTM), which was exclusively licensed to Astellas Pharma and advanced as ASP2957 into the Phase I/II VALOR trial, plus preclinical programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.
The business model was that of a research-stage biotech: Kate generated no product revenue and monetized through scientific publications, conference presence, and strategic licensing partnerships rather than direct commercialization. Following its acquisition, Kate's programs and expertise were integrated into Novartis's consolidated genetic medicine research operations in San Diego, joining prior acquisitions including AveXis and DTx Pharma. The founders included Sharif Tabebordbar (Chief Scientific Officer), Kevin Forrest (Chief Executive Officer), and Mark Fielden (SVP of Nonclinical Development), with Beth Seidenberg serving as Chair of the Board.
Kate Therapeutics firmographics
Firmographics- Name
- Kate Therapeutics
- Legal name
- Kate Therapeutics Inc.
- Website
- https://katetherapeutics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Kate Therapeutics was a San Diego-based biotechnology company that developed next-generation gene therapies for muscle and heart diseases using its proprietary MyoAAV capsid platform; the company was acquired by Novartis in 2024 for approximately $1.1 billion.
- Ownership category
- akta.pro rank
Kate Therapeutics industry classification
Industry- Product category
- Gene Therapy - Rare Neuromuscular & Cardiac Diseases
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)
- akta.pro secondary industries
- Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
Keywords
Where Kate Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Kate Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
Kate Therapeutics product offering
Product offeringCore offering
Kate Therapeutics developed next-generation gene therapies for muscle and heart diseases, built on a proprietary capsid and cargo delivery platform. Its lead asset, KT430, targeted X-linked myotubular myopathy (XLMTM) and was licensed exclusively to Astellas Pharma (incorporated into ASP2957), while additional pipeline programs addressed myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. The company's MyoAAV capsid technology enabled targeted muscle delivery at approximately 100-fold lower doses than earlier gene therapy approaches, addressing liver toxicity concerns that had hindered prior programs.
Product overview
Kate Therapeutics was a gene therapy company focused on developing targeted delivery platforms for muscle and heart diseases. The company built its business around a novel capsid and cargo technology platform, including the proprietary MyoAAV capsid technology that enables improved muscle targeting. The pipeline included KT430 (licensed to Astellas for X-linked myotubular myopathy) and programs targeting myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. Kate Therapeutics was acquired by Novartis in 2024 for approximately $1.1 billion.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel Capsid and Cargo Technology Platform
Quantifiable outcome
- MyoAAV3.8 demonstrated approximately 100-fold lower dosing requirement than AT132 while maintaining improved muscle targeting in preclinical studies
Companies that use Kate Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Kate Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Kate Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Novartis AGflagshipNovartis acquired Kate Therapeutics in 2024 for $1.1 billion as part of its strategy to build a leading gene therapy capability. Kate's programs and expertise in neuromuscular diseases were integrated into Novartis's consolidated genetic medicine research operations in San Diego, combining with AveXis, DTx Pharma, and other acquisitions under Executive Director Bryan Laffitte.
- Astellas Pharma Inc.coreKate Therapeutics granted Astellas Pharma Inc. an exclusive license to develop KT430 (later incorporated into ASP2957) for X-linked myotubular myopathy (XLMTM). Astellas advanced this therapy into Phase I/II VALOR trial using the MyoAAV capsid technology from Kate. The partnership represents a significant licensing arrangement for muscle disease gene therapies.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Kate Therapeutics competitors and assessment
Company assessmentDirect peers
- uniQure: Gene therapy company with AAV-based platform and clinical programs in rare neuromuscular and metabolic diseases. Comparable as a developer of AAV-delivered gene therapies for rare genetic disorders.
- Regenxbio: Clinical-stage gene therapy company with proprietary AAV capsid platform (NAV Technology) used across multiple partners for neuromuscular and rare disease indications. Comparable to Kate's MyoAAV capsid platform approach.
- Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular disorders. Comparable to Kate in muscle-targeted AAV capsid approach and rare muscle disease focus.
- Sarepta Therapeutics: Commercial-stage gene therapy leader for Duchenne muscular dystrophy and other neuromuscular diseases using AAV-based delivery. Directly comparable to Kate as a muscle-directed AAV gene therapy developer targeting rare neuromuscular indications.
Emerging players
- Lexeo Therapeutics: Clinical-stage AAV gene therapy company focused on cardiac and neuromuscular diseases. Comparable to Kate in combining cardiac and muscle targets with AAV delivery technology.
- Tenaya Therapeutics: Clinical-stage gene therapy company developing treatments for genetic heart disease, including cardiomyopathy. Comparable to Kate's cardiac gene therapy component and rare disease focus.
- Affinia Therapeutics: Emerging gene therapy company developing novel AAV capsids for muscle and central nervous system diseases. Comparable to Kate as a capsid-engineering platform company targeting muscle tissue.
Broad incumbents
- BioMarin Pharmaceutical: Large rare disease biopharmaceutical company developing AAV gene therapies (e.g., Roctavian for hemophilia A). Comparable to Kate as a rare disease gene therapy developer, though BioMarin operates at significantly larger scale across multiple therapeutic areas.
- Pfizer: Global pharmaceutical company with gene therapy capabilities including AAV-based treatments for neuromuscular diseases (e.g., Beqvez for hemophilia B). Comparable as a large-pharma acquirer/developer of gene therapy platforms.
Others
- Astellas Pharma: Japanese pharmaceutical company that was Kate's exclusive licensee for KT430 (ASP2957) for XLMTM and the developer of AT132, whose liver toxicity issues Kate's MyoAAV capsid was designed to address. Relevant as Kate's primary commercial partner and a benchmark for muscle-directed AAV development.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Kate Therapeutics social profiles
Digital presenceKate Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kate Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Kate Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kate Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kate Therapeutics
What does Kate Therapeutics do?
Kate Therapeutics developed next-generation gene therapies for muscle and heart diseases, built on a proprietary capsid and cargo delivery platform. Its lead asset, KT430, targeted X-linked myotubular myopathy (XLMTM) and was licensed exclusively to Astellas Pharma (incorporated into ASP2957), while additional pipeline programs addressed myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy. The company's MyoAAV capsid technology enabled targeted muscle delivery at approximately 100-fold lower doses than earlier gene therapy approaches, addressing liver toxicity concerns that had hindered prior programs.
Is Kate Therapeutics a public or private company?
Kate Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Kate Therapeutics founded?
Kate Therapeutics was founded in 2020. It employs 11 to 50 people.
Where is Kate Therapeutics based?
Kate Therapeutics is headquartered in San Diego, United States, in the North America region.
Who are Kate Therapeutics's main competitors?
Direct peers on record are uniQure, Regenxbio, Solid Biosciences and Sarepta Therapeutics. Emerging players are Lexeo Therapeutics, Tenaya Therapeutics and Affinia Therapeutics. Broad incumbents are BioMarin Pharmaceutical and Pfizer. Astellas Pharma is listed as an others.
Does Kate Therapeutics have an API?
No public API is recorded for Kate Therapeutics.
What industry is Kate Therapeutics in?
Kate Therapeutics's product category is Gene Therapy - Rare Neuromuscular & Cardiac Diseases. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAL, Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery). Its NAICS code is 325414 and its SIC code is 2834.